FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions relates to pharmaceutical chemistry and includes specific compounds indicated in cl. 1 of the claims, and a pharmaceutical composition based on them.
EFFECT: compounds having inhibitory activity relatively to Bcl-2.
14 cl, 7 tbl, 311 ex
Title | Year | Author | Number |
---|---|---|---|
INHIBITOR OF CERTAIN PROTEIN KINASES | 2016 |
|
RU2732952C2 |
PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
CERTAIN PROTEIN KINASE INHIBITORS | 2015 |
|
RU2671494C2 |
N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM | 2007 |
|
RU2364597C1 |
APOPTOSIS INDUCING AGENTS FOR TREATING MALIGNANT NEW GROWTH, AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535347C2 |
APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATING MALIGNANT TUMOURS AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2573832C2 |
Authors
Dates
2022-10-27—Published
2018-04-17—Filed